Alkem Laboratories Ltd Stock Price Today (NSE: ALKEM)
Fundamental Score
Alkem Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Alkem Laboratories Ltd share price today is ₹5464.00, up +0.00% on NSE/BSE as of 18 February 2026. Alkem Laboratories Ltd (ALKEM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹67.08K (Cr). The 52-week high for ALKEM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 28.54x, ALKEM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 19.39% and a debt-to-equity ratio of 0.18.
Alkem Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Alkem Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Alkem Laboratories Share Price: A Financial Analysis for Growth
The pharmaceutical industry is currently experiencing a shift towards increased generic drug adoption globally, driven by cost pressures and patent expirations. This environment presents both opportunities and challenges for Indian pharmaceutical companies. This analysis examines the "Alkem Laboratories share price," currently at ₹5587.5, through a growth lens, considering its financial metrics and competitive positioning. A key indicator of financial health is the Price-to-Earnings (PE) ratio, standing at 28.54 for Alkem Laboratories. This indicates the market's valuation of Alkem’s earnings relative to its share price.
A critical factor in evaluating a company's long-term growth potential is its Return on Capital Employed (ROCE). Alkem Laboratories boasts a ROCE of 20.38%. This indicates the company's efficiency in generating profits from its capital investments. A high ROCE, such as this, directly contributes to widening the company's economic moat, making it more difficult for competitors to erode its profitability and market share. The reinvestment of these returns back into the business can further fuel growth and innovation.
Comparing Alkem Laboratories Ltd with peers is essential. For example, contrasting Alkem to
Mankind Pharma Ltd regarding management quality, as reflected in strategic decisions and operational efficiency, would provide a valuable comparative insight. While metrics like revenue growth and profitability margins are crucial, the quality of management significantly impacts the long-term sustainability and adaptability of a company within a dynamic sector.This analysis is a component of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra, to ensure a robust and balanced perspective. It is important to note that this analysis is observational and based on available data and does not constitute a recommendation to buy, sell, or hold shares of Alkem Laboratories Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alkem Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALKEM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (19.39%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.38%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.30%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (17.17%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (22.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹6390.70 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.20%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 31.40%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Alkem Laboratories Ltd Financial Statements
Comprehensive financial data for Alkem Laboratories Ltd including income statement, balance sheet and cash flow
About ALKEM (Alkem Laboratories Ltd)
Alkem Laboratories Ltd (ALKEM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹67.08K (Cr). Alkem Laboratories Ltd has delivered a Return on Equity (ROE) of 19.39% and a ROCE of 20.38%. The debt-to-equity ratio stands at 0.18, reflecting the company's capital structure. Investors tracking ALKEM share price can monitor key metrics including P/E ratio, promoter holding of 51.20%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
ALKEM Share Price: Frequently Asked Questions
What is the current share price of Alkem Laboratories Ltd (ALKEM)?
As of 18 Feb 2026, 10:38 am IST, Alkem Laboratories Ltd share price is ₹5464.00. The ALKEM stock has a market capitalisation of ₹67.08K (Cr) on NSE/BSE.
Is ALKEM share price Overvalued or Undervalued?
ALKEM share price is currently trading at a P/E ratio of 28.54x, compared to the industry average of 31.77x. Based on this relative valuation, the Alkem Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ALKEM share price?
The 52-week high of ALKEM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Alkem Laboratories Ltd share price?
Key factors influencing ALKEM share price include quarterly earnings growth (Sales Growth: 17.17%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alkem Laboratories Ltd a good stock for long-term investment?
Alkem Laboratories Ltd shows a 5-year Profit Growth of 13.93% and an ROE of 19.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing in ALKEM shares.
How does Alkem Laboratories Ltd compare with its industry peers?
Alkem Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ALKEM share price P/E of 28.54x and ROE of 19.39% against the industry averages to determine competitive standing.
What is the P/E ratio of ALKEM and what does it mean?
ALKEM share price has a P/E ratio of 28.54x compared to the industry average of 31.77x. Investors pay ₹29 for every ₹1 of annual earnings.
How is ALKEM performing according to Bull Run's analysis?
ALKEM has a Bull Run fundamental score of 59.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ALKEM belong to?
ALKEM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alkem Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for ALKEM?
ALKEM has an ROE of 19.39%, which indicates excellent management efficiency. ROE measures how efficiently Alkem Laboratories Ltd generates profits from shareholders capital.
How is ALKEM debt-to-equity ratio and what does it indicate?
ALKEM has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk.
What is ALKEM dividend yield and is it a good dividend stock?
ALKEM offers a dividend yield of 0.80%, meaning you receive ₹0.80 annual dividend for every ₹100 invested in Alkem Laboratories Ltd shares.
How has ALKEM share price grown over the past 5 years?
ALKEM has achieved 5-year growth rates of: Sales Growth 9.21%, Profit Growth 13.93%, and EPS Growth 13.93%.
What is the promoter holding in ALKEM and why does it matter?
Promoters hold 51.20% of ALKEM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Alkem Laboratories Ltd.
What is ALKEM market capitalisation category?
ALKEM has a market capitalisation of ₹67075 crores, placing it in the Large-cap category.
How volatile is ALKEM stock?
ALKEM has a beta of N/A. A beta > 1 suggests the Alkem Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ALKEM operating profit margin trend?
ALKEM has a 5-year average Operating Profit Margin (OPM) of 18.30%, indicating the company's operational efficiency.
How is ALKEM quarterly performance?
Recent quarterly performance shows Alkem Laboratories Ltd YoY Sales Growth of 17.17% and YoY Profit Growth of 11.10%.
What is the institutional holding pattern in ALKEM?
ALKEM has FII holding of 9.47% and DII holding of 21.93%. Significant institutional holding often suggests professional confidence in the Alkem Laboratories Ltd stock.